All In Biotech

Drug Trial Radar · NCT00790933

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease

Last checked: Nov 20, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,243

Actual

Start

May 22, 2009

Primary completion

Oct 31, 2017

Study completion Oct 31, 2017

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.

Conditions

  • Ulcerative Colitis
  • Crohn's Disease

Interventions

  • VedolizumabDrug

    Vedolizumab intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to approximately 8.5 years)
  2. Number of Participants With Markedly Abnormal Safety Laboratory FindingsTime frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)
  3. Percentage of Participants With at Least One Clinically Significant Mean Change Over Time in Vital Sign MeasurementsTime frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)
  4. Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) FindingsTime frame: From first dose of study drug in this study through 16 weeks after the last dose of study drug (Up to 8.5 years)
  5. Time to Major Inflammatory Bowel Disease (IBD) - Related EventsTime frame: Baseline (Prior to first dose of study drug in C13008) up to end of study (approximately up to 8.5 years)
  6. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
  7. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
  8. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
  9. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
  10. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
  11. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
  12. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
  13. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
  14. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
  15. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
  16. Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Scores at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
  17. Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
  18. Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
  19. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
  20. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
  21. Change From Baseline in Short Form-36 (SF-36) Physical Component at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
  22. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
  23. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
  24. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
  25. Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
  26. Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
  27. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
  28. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
  29. Change From Baseline in Short Form-36 (SF-36) Physical Component Scores at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
  30. Change From Baseline in Short Form-36 (SF-36) Mental Component Scores at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
  31. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
  32. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
  33. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
  34. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
  35. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
  36. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
  37. Change From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
  38. Change From Baseline in Short Form-36 (SF-36) Mental Component Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
  39. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
  40. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 28Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 28
  41. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
  42. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 52Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 52
  43. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
  44. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 76Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 76
  45. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
  46. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 100Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 100
  47. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
  48. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 124Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 124
  49. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
  50. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 148Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 148
  51. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
  52. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 172Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 172
  53. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
  54. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 196Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 196
  55. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
  56. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 248Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 248
  57. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
  58. Change From Baseline in EuroQol 5D Health States (EQ-5D) Visual Analog Scale (VAS) Score at Week 300Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 300
  59. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Composite Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352
  60. Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) Health States Visual Analog Scale (VAS) Score at Week 352Time frame: Baseline (prior to first dose of study drug in C13008; for rollover participants this was the last assessment from the previous study) and Week 352

Locations

41 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Lafayette, Colorado

  • Site not named

    Littleton, Colorado

  • Site not named

    Thornton, Colorado

  • Site not named

    Hamden, Connecticut

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Topeka, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Chevy Chase, Maryland

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Cheektowaga, New York

  • Site not named

    New York, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Elkin, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Germantown, Tennessee

  • Site not named

    San Antonio, Texas

  • Site not named

    Tyler, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Leuven, Belgium

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Saskatoon, Saskatchewan, Canada

  • Site not named

    Prague, Czechia

  • Site not named

    Halle, Saint, Germany

  • Site not named

    Szekszárd, Hungary

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Kuala Lumpur, Malaysia

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.